Evidence map›Paper›PMID 10557281›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1999

Mechanism by which the IFN-beta enhanceosome activates transcription.

J Yie, K Senger, D Thanos

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Chromatin remodeling effects on enhancer activity.Cellular and molecular life sciences : CMLS · 2016
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

J YieDepartment of Biochemistry, Columbia University, 630 West 168th Street, New York, NY 10032, USA.
K Senger
D Thanos

Funding

HIGH MOBILITY GROUP PROTEIN IN GENE TRANSCRIPTIONR01GM054605 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI THANOS, DIMITRIS · 1996 to 2002
$885k
TRAINING FOR CAREERS IN MOLECULAR OPHTHALMOLOGYT32EY007105 · NEI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HIRSH, DAVID I · 1988 to 1999
–
NEI NIH HHS 1T32 EY07105NEI NIH HHS T32 EY007105NIGMS NIH HHS 1RO1GM54605NIGMS NIH HHS R01 GM054605
6 · The paper itself

Abstract

We demonstrate that in contrast to previous findings by using simple synthetic promoters or activators, the natural IFN-beta enhanceosome activates transcription by causing a dramatic increase of the rate by which preinitiation complexes assemble at the promoter. This effect totally depends on the recruitment of the CBP-PolII holoenzyme by the enhanceosome, because its depletion from the extract decelerates the rate of transcription. However, addition of the CBP-PolII holoenzyme back to these extracts fully restores the speed by which the enhanceosome activates transcription. Strikingly, preincubation of the enhanceosome with the CBP-RNA PolII holoenzyme complex results in instant assembly of preinitiation complexes. In contrast, individual IFN-beta gene activators function solely by increasing the number of functional preinitiation complexes and not the rate of their assembly. Thus, fast recruitment of the CBP-RNA PolII holoenzyme complex is critical for the rapid activation of IFN-beta gene expression by virus infection.

Indexed as

Enhancer Elements, GeneticHeLa CellsHumansInterferon-betaNuclear ProteinsPromoter Regions, GeneticRNA Polymerase IIITrans-ActivatorsTranscriptional ActivationInterferon-betaNuclear ProteinsRNA Polymerase IIITrans-Activators

Identifiers

PMID10557281
PMCPMC23908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.